Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass
Authors' conclusion
We demonstrated romosozumab's efficacy in BMD increment in premenopausal women.
Study context
- Population
- Premenopausal women with low bone mass (mean age 37.0 years; median BMI 18.8 kg/m²)
- Participants
- 25 / 12 / 9 / 4 / 5
- Exposure
- Romosozumab vs drug-naïve controls
- ROMOn = 25
- Glucocorticoid-induced osteoporosis (GIOP)n = 12
- Idiopathic osteoporosis (IOP)n = 9
- PLOn = 4
- Controln = 5reference
- Outcome
- Change in BMD and TBS from baseline
- Follow-up
- One year
Main finding
As reported in the abstract
Change from baseline in LS BMD, FN BMD and TBS (ROMO)
| Group | Value | Lumbar spine (LS) bone mineral density (BMD) change P | Femur neck (FN) BMD change P | Trabecular bone score (TBS) change P |
|---|---|---|---|---|
| ROMO | 12.8% (range 8.2–19.3) | p < 0.001 | ||
| ROMO | 4.6% (range - 0.6-10.7) | p = 0.016 | ||
| ROMO | 4.1% ± 3.8 | p < 0.001 |
Value
ROMO12.8% (range 8.2–19.3)
ROMO4.6% (range - 0.6-10.7)
ROMO4.1% ± 3.8
Lumbar spine (LS) bone mineral density (BMD) change P
ROMOp < 0.001
ROMO— not stated in the abstract
ROMO— not stated in the abstract
Femur neck (FN) BMD change P
ROMO— not stated in the abstract
ROMOp = 0.016
ROMO— not stated in the abstract
Trabecular bone score (TBS) change P
ROMO— not stated in the abstract
ROMO— not stated in the abstract
ROMOp < 0.001
Observational data: associations, not effects.
Further findings
BMD change by subgroup · one year
- GIOP and IOP: significant increase in LS BMD
- IOP: significant increase in FN BMD
Original publication
Effect of romosozumab on bone mineral density and trabecular bone score in premenopausal women with low bone mass. Osteoporos Int. Published 15 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →